RE:RE:RE:RE:RE:RE:RE:RE:7%Stinzo wrote: jokes, CZO removed the company presentation on the website....it was from Jan 2023 and promising alot probably
The July 12, 2023 presentation is on their website. The news release with the financials, issued less than one month ago, had timelines for the avenanthramide clinical trial, PGX scale-up. They also said they were very active concerning strategic initiatives. This could mean new revenue opportunities and even a potential reverse-merger to NASDAQ, etc. This could involve a major change in the presentation. There was no mention of a partnership deal for PGX in the financial news release. That could be contingent on the PGX scale-up underway now. There is also the issue concerning base business revenue. Has reordering recommenced as expected. Given trailing revenue revenue may underperform this year; however with new potential revenue sources for 2024 there may be a path new path moving forward. The fibrosis trial has been delayed for a toxicology study as noted in the last news release. The avenanthramide malting technology has research commercial scale and they are trying to validate it with repeatability.